Globe Newswire (Thu, 23-Jul 3:09 AM ET)
Genenta-Backed Sphia High Tech Reports Fiscal Year 2025 Results
Globe Newswire (Wed, 22-Jul 4:00 AM ET)
Genenta’s Bold Shift: Strategic Transformation and Defense Sector Expansion Signal New Era for GNTA
Market Chameleon (Tue, 27-Jan 4:53 AM ET)
Market Chameleon (Fri, 24-Oct 5:52 AM ET)
Market Chameleon (Fri, 24-Oct 3:05 AM ET)
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
Genenta Science S.P.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol GNTA.
As of August 10, 2026, GNTA stock price was flat at $1.30 with 30,816 million shares trading.
GNTA has a beta of 0.21, meaning it tends to be less sensitive to market movements. GNTA has a correlation of 0.00 to the broad based SPY ETF.
GNTA has a market cap of $30.46 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, GNTA traded as high as $10.00 and as low as $.55.
GNTA has underperformed the market in the last year with a price return of -65.8% while the SPY ETF gained +23.5%. However, in the short term, GNTA had mixed performance relative to the market. It has outperformed in the last 3 months, returning +103.1% vs +5.9% return in SPY. But in the last 2 weeks, GNTA shares have been beat by the market, returning -18.2% compared to an SPY return of +4.6%.
GNTA support price is $1.19 and resistance is $1.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GNTA shares will trade within this expected range on the day.